In Q1 2024, Perceptive Advisors held 86 positions worth $5.2B. They initiated 20 new positions and exited 29. Their largest holding was CERE ($456.3M). Portfolio value grew +28.4% versus the prior quarter.
Frequently asked questions
What stocks did Perceptive Advisors own in Q1 2024?
Perceptive Advisors held 86 biotech stocks in their 13F portfolio in Q1 2024. Their top positions include CERE, FOLD, IOVA, ACLX, NUVL. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Perceptive Advisors's portfolio worth in Q1 2024?
Perceptive Advisors's tracked biotech portfolio was worth $5.2B across 86 positions, with total assets under management of approximately $8B. Portfolio values are based on 13F filings with the SEC.
What did Perceptive Advisors buy in Q1 2024?
Perceptive Advisors initiated 20 new positions in Q1 2024, including VRNA, CGON, PRAX, CNTA, OCUL and 15 more. They also increased 34 existing positions.
What did Perceptive Advisors sell in Q1 2024?
Perceptive Advisors fully exited 29 positions in Q1 2024, including SNYNF, PRTO, RXDX, LRMR, DRIO and 24 more. They also trimmed 14 existing positions.
Is Perceptive Advisors a biotech fund?
Clinical-stage biotech specialist known for deep scientific due diligence and concentrated bets on binary catalysts like FDA approvals and pivotal trial readouts. Edelman and team leverage decades of pattern recognition in drug development to identify asymmetric risk/reward setups.
Want AI analysis, insider signals, and catalyst overlays for Perceptive Advisors?
View latest Perceptive Advisors portfolio →